Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Terminated 1Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1

Conditions

Breast Neoplasms 6Triple Negative Breast Neoplasms 3Recurrence 3Prostatic Neoplasms 3Urinary Bladder Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Carcinoma, Non-Small-Cell Lung 2Turcot syndrome 1Thyroid Neoplasms 1Tertiary Lymphoid Structures 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Non-Muscle Invasive Bladder Neoplasms 1Multiple Myeloma 1Mucopolysaccharidosis I 1Mesothelioma, Malignant 1Lymphoma, T-Cell, Peripheral 1Liposarcoma 1Inhibition of Autophagy Synergizes Anti-tumor Effect 1Immunoblastic Lymphadenopathy 1Hodgkin Disease 1Genetic Diseases, Inborn 1Gastro-enteropancreatic neuroendocrine tumor 1Esophageal Squamous Cell Carcinoma 1

Interventions

Cyclophosphamide 151Dexamethasone 140Rituximab 83fludarabine 78Cytarabine 69Lenalidomide 68Bortezomib 63fludarabine phosphate 62Gemcitabine 62venetoclax 54Etoposide 53pembrolizumab 52pomalidomide 48Paclitaxel 48Cisplatin 47Carboplatin 47Peripheral Blood Stem Cell Transplantation 46Filgrastim 40Radiotherapy 39Calcium Dobesilate 36Busulfan 36Methotrexate 34Melphalan 34Bevacizumab 33carfilzomib 32Cyclosporine 32Azacitidine 32Mycophenolic Acid 29Vincristine 28Temozolomide 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Recurrence × Clinical Trials, Phase II as Topic × Clear all
NCT05958121 2025-11-18

IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors

Immatics Biotechnologies GmbH

Phase 1/2 Recruiting
145 enrolled

Neoplasms, Recurrence

NCT03683277 2025-02-19

IFM2014-01

Intergroupe Francophone du Myelome

Phase 2 Terminated
26 enrolled
Plasma cell

Multiple Myeloma, Recurrence, Genetic Diseases, Inborn

NCT01572519 2020-11-20

A Study of JNJ-40346527 in Patients With Relapsed or Refractory Hodgkin Lymphoma

Janssen Research & Development, LLC

Phase 1 Completed
21 enrolled
Lymphoid

Hodgkin Disease, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡